Advertisement

Hopkins Biologist Saul Sharkis Dies at 72; Studied Blood Stem Cells’ Role in BMT

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Saul Sharkis, a scientist who studied the biology of blood stem cells and how they could be used to treat cancer through bone marrow transplantation, died Sept. 4. He was 72.

Sharkis was a professor of oncology at the Johns Hopkins University School of Medicine and a faculty member in the Johns Hopkins Kimmel Cancer Center for more than 40 years.

A native of New York, Sharkis earned his B.A. from Hunter College and his master’s and doctoral degrees from New York University. After completing his postdoctoral research at National Naval Medical Center in Bethesda, Maryland, he was recruited to the faculty of the Johns Hopkins University School of Medicine’s Department of Oncology.

Sharkis was among the first to isolate and study hematopoietic stem cells. His research was important to the progress of bone marrow and stem cell transplants because it helped reveal the mechanisms of engraftment. His work also uncovered the biology of stem cells, isolating and tracking a stem cell population to show that small numbers of stem cells can reconstitute bone marrow following transplant.

Advertisement

He also studied the plasticity of blood stem cells and developed research models to explore their capacity to develop into other cells, particularly epithelial cells in the liver, pancreas, kidney, breast and intestine. These cells line the organs and are often the site where cancers begin. His hope was that one day, stem cells could be use as cellular therapy to treat cancers.

“Saul inspired us with his dedication, invaluable knowledge and experience. He was a brilliant yet humble man, a superb scientist and a Johns Hopkins innovator,” said William Nelson, director of the Johns Hopkins Kimmel Cancer. “He will be sorely missed by countless residents, fellows and colleagues.”

He is survived by brother, Alan, and sister-in-law, Anne, as well as nieces and nephews.

Advertisement
Advertisement
Table of Contents
Advertisement
Advertisement

YOU MAY BE INTERESTED IN

Just consider for a minute if this was the first year of running your lab, if you were on the job market as a physician or scientist right now, if you were a resident contemplating a career in cancer research after fellowship, if you were a graduate student or postdoc, if you were an undergraduate or a technician who was looking toward graduate school.
The immune system can be a powerful tool to control cancer. Immune cells within our body detect cancer cells and release payloads that kill them. Transformative science in the last decade has led to the development of therapies that enhance the ability of our immune cells to carry out this function. These therapies, including checkpoint blockade and CAR-T cells, have been lifesaving for many patients that before had untreatable cancer. But, sadly, a majority of patients with advanced solid tumors still succumb to their disease. 
Advertisement
Advertisement